Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting pathological ERK1/2 signaling in cancer and beyond

5 Sept 2025

Abstract excerpt

Dysregulation of the RAF-MEK-ERK1/2 pathway is involved in the pathoetiology of many diseases. Its central role in cancer has led to the development of drugs targeting upstream receptors, RAS, and kinases in the extracellular signal-regulated kinase 1 (ERK1) and 2 (ERK2) signaling cascade. The use of these drugs in cancer therapy - together with ongoing monitoring of their effectiveness, evolving side-effects,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Cytokine Signaling Pathways and Interactions
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40914707
DOI: 10.1016/j.molmed.2025.08.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting pathological ERK1/2 signaling in cancer and beyondPMID 40914707Read ↗

The MEK/ERK Network as a Therapeutic Target in Human CancerSemantic proximity Read ↗

Mutations That Confer Drug-Resistance, Oncogenicity and Intrinsic Activity on the ERK MAP Kinases-Current State of the Art.Semantic proximity Read ↗

Targeting Ras-ERK cascade by bioactive natural products for potential treatment of cancer: an updated overviewSemantic proximity Read ↗

Inhibitors of the ERK mitogen-activated protein kinase cascade for targeting RAS mutant cancers.Semantic proximity Read ↗

Deciphering the RAS/ERK pathway in vivo.Semantic proximity Read ↗

Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trialsSemantic proximity Read ↗

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapySemantic proximity Read ↗

RAS/RAF/MEK Inhibitors in OncologySemantic proximity Read ↗

Oncogenic signaling of MEK5-ERK5.Semantic proximity Read ↗

Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancerSemantic proximity Read ↗

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.Semantic proximity Read ↗

Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS SignallingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.